TY - JOUR
T1 - Laboratory and clinical studies on cefdinir
AU - Irabu, Yuei
AU - Tamaki, Kazunori
AU - Fukuhara, Hiroshi
AU - Nakamura, Hiroaki
AU - Kaneshima, Hiroshi
AU - Shimoji, Katsuyoshi
AU - Kitsukawa, Keizou
AU - Shigeno, Yoshiteru
AU - Saito, Atsushi
AU - Taira, Shinko
AU - Nakasone, Isamu
AU - Kusano, Nobuchika
AU - Hokama, Seitetsu
PY - 1989
Y1 - 1989
N2 - We performed basic and clinical studies on cefdinir (CFDN), a new cephalosporin, with the followings. 1. Antimicrobial activity, concentration in plasma and sputum The minimum inhibitory concentrations (MICs) of CFDN against a total of 348 clinically isolated strains were determined and compared with those of cefaclor, ampicillin, cefteram, cefixime and cefotiam, using the MIC-2000 System (Dynatech Laboratories). CFDN had wide antimicrobial activity against these clinically isolated strains except Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. The maximum plasma concentration was 0.841μ g/ml, and the maximum sputum concentration was 0.076μg/ml. 2. Clinical efficacy CFDN was given in a daily dose of 300 mg or 600 mg to 1 patient with acute tonsillitis, 1 with acute bronchitis, 5 with chronic bronchitis, 1 with bronchiectasis, 3 with diffuse panbronchiolitis and 2 with bacterial pneumonia for 5-14 days. Clinical response was excellent in 1 patient, good in 9, fair in 2, and poor in 1, the clinical efficacy rate being 77%. Skin eruption as a side effect was observed in one patient. Altered laboratory findings were: 1 case of transient elevation of GPT, 1 of transient elevation of GPT and Al-P, and 1 of increase in eosinophils.
AB - We performed basic and clinical studies on cefdinir (CFDN), a new cephalosporin, with the followings. 1. Antimicrobial activity, concentration in plasma and sputum The minimum inhibitory concentrations (MICs) of CFDN against a total of 348 clinically isolated strains were determined and compared with those of cefaclor, ampicillin, cefteram, cefixime and cefotiam, using the MIC-2000 System (Dynatech Laboratories). CFDN had wide antimicrobial activity against these clinically isolated strains except Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. The maximum plasma concentration was 0.841μ g/ml, and the maximum sputum concentration was 0.076μg/ml. 2. Clinical efficacy CFDN was given in a daily dose of 300 mg or 600 mg to 1 patient with acute tonsillitis, 1 with acute bronchitis, 5 with chronic bronchitis, 1 with bronchiectasis, 3 with diffuse panbronchiolitis and 2 with bacterial pneumonia for 5-14 days. Clinical response was excellent in 1 patient, good in 9, fair in 2, and poor in 1, the clinical efficacy rate being 77%. Skin eruption as a side effect was observed in one patient. Altered laboratory findings were: 1 case of transient elevation of GPT, 1 of transient elevation of GPT and Al-P, and 1 of increase in eosinophils.
KW - Cefdinir
UR - http://www.scopus.com/inward/record.url?scp=0024839623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024839623&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.37.Supplement2_603
DO - 10.11250/chemotherapy1953.37.Supplement2_603
M3 - Article
AN - SCOPUS:0024839623
SN - 0009-3165
VL - 37
SP - 603
EP - 611
JO - Chemotherapy
JF - Chemotherapy
ER -
